A V n i e g n a h C n a e M 6 12 18 24 ™ o o o + = o o o o o o o • • • Loading doses Primary Endpoint Week 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Tarcocimab tedromer Q12W, Q16W or Q20W dosing based on 5 mg pre-specified disease activity Aflibercept 2 mg Tarcocimab injection Aflibercept individualized Primary Endpoint: treatment/sham Mean change in BCVA averaged over Weeks 48 & 52 Aflibercept injection Absolute BCVA Aflibercept Q8W Tarcocimab Q20W Tarcocimab Q16W Tarcocimab Q12W 80 69.7 aflibercept Q8W 70 68 ...